Clinical trial
Prediction of Everolimus-induced Interstitial Lung Disease in Breast Cancer Patients; Maximizing Efficacy by Reducing Toxicity
NCT01978171 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prediction of Everolimus-induced Interstitial Lung Disease in Breast Cancer Patients; Maximizing Efficacy by Reducing Toxicity
- Lead sponsor
- Radboud University Medical Center
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2014
- Completion date
- January 15, 2018
- Enrollment
- 27 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.